Outlook Therapeutics OTLK
NASDAQ OTLK
$0.59 +0.02 (+3.51%)
At close: Oct 2, 2026 · 4:00 PM EDT

Outlook Therapeutics (OTLK) Cost of Revenue (2025 - 2026)

Updated

Outlook Therapeutics' Cost of Revenue was $16,965 in fiscal Q3 2026 (quarter ended Jun 30, 2026), down 96.1% from $439,815 a year earlier and down 88.6% from the prior quarter.

Analysis

Outlook Therapeutics (OTLK) Cost of Revenue (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Outlook Therapeutics' Cost of Revenue was $1.11 million through Jun 30, 2026; for FY2025 (ended Sep 30, 2025), it was $1.36 million.

  • Per Business Quant data, OTLK's Cost of Revenue in the three fiscal quarters before Q3 2026 was $149,327 (Q2 2026), $29,626 (Q1 2026) and $916,515 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 8.05 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.29 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.52 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 1.58 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.09 Bn
10 Outlook Therapeutics 80.68 Mn 44.93 Mn -8,265.00 16,965.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 16,965.00
Mar 31, 2026 149,327.00
Dec 31, 2025 29,626.00
Sep 30, 2025 916,515.00
Jun 30, 2025 439,815.00
API Access

Outlook Therapeutics Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=OTLK&period=max&api_key=YOUR_API_KEY